Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology and a median survival from diagnosis of 3-5 years. Despite extensive research efforts, its etiology in humans still remains largely unknown, and no curative drug therapies are available. With a gradually increasing worldwide incidence, IPF still presents a major challenge in clinical research due to its appreciable heterogeneity among individual patients in disease course and the lack of easily reproducible surrogate markers for patient relevant outcomes. Currently clinicians and researchers apply a panel of functional, radiological and histopathological indices to stratify patients into distinct phenotypic patterns of disease progression. However, none of these indicators can reliably predict not only treatment responsiveness but more importantly disease behavior, thus allowing clinicians to promptly apply aggressive therapeutic approaches to prevent or ameliorate acute exacerbation. Furthermore, on the contrary to molecular biomarkers, physiologic prognosticators provide no insights into disease mechanism and thus are unlikely to identify distinct molecular phenotypes of the disease. In the dawn of the “fibromics” era the need for disease stratification based on molecular phenotypes and implementation of personalized medicine therapeutic approaches is still unmet. Molecular biomarkers lie in the core of personalized medicine and therefore represent the main focus of this review article. Limitations that hamper their widespread clinical applicability along with future perspectives on how to address these major caveats and launch IPF biomarkers to the same trajectory as to tumor biomarkers in oncology are also discussed.
Keywords: Biomarkers, Idiopathic Pulmonary Fibrosis, Alveolar epithelial cell injury, Immunity, Extracellular matrix.
Current Topics in Medicinal Chemistry
Title:Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
Volume: 16 Issue: 14
Author(s): Argyris Tzouvelekis, Jose Herazo-Maya, Koji Sakamoto and Demosthenes Bouros
Affiliation:
Keywords: Biomarkers, Idiopathic Pulmonary Fibrosis, Alveolar epithelial cell injury, Immunity, Extracellular matrix.
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology and a median survival from diagnosis of 3-5 years. Despite extensive research efforts, its etiology in humans still remains largely unknown, and no curative drug therapies are available. With a gradually increasing worldwide incidence, IPF still presents a major challenge in clinical research due to its appreciable heterogeneity among individual patients in disease course and the lack of easily reproducible surrogate markers for patient relevant outcomes. Currently clinicians and researchers apply a panel of functional, radiological and histopathological indices to stratify patients into distinct phenotypic patterns of disease progression. However, none of these indicators can reliably predict not only treatment responsiveness but more importantly disease behavior, thus allowing clinicians to promptly apply aggressive therapeutic approaches to prevent or ameliorate acute exacerbation. Furthermore, on the contrary to molecular biomarkers, physiologic prognosticators provide no insights into disease mechanism and thus are unlikely to identify distinct molecular phenotypes of the disease. In the dawn of the “fibromics” era the need for disease stratification based on molecular phenotypes and implementation of personalized medicine therapeutic approaches is still unmet. Molecular biomarkers lie in the core of personalized medicine and therefore represent the main focus of this review article. Limitations that hamper their widespread clinical applicability along with future perspectives on how to address these major caveats and launch IPF biomarkers to the same trajectory as to tumor biomarkers in oncology are also discussed.
Export Options
About this article
Cite this article as:
Tzouvelekis Argyris, Herazo-Maya Jose, Sakamoto Koji and Bouros Demosthenes, Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis, Current Topics in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1568026616666150930120959
DOI https://dx.doi.org/10.2174/1568026616666150930120959 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension in Chronic Kidney Disease: Novel Insights
Current Hypertension Reviews Effects of a Long-Term Treatment with an Antioxidant Pyridoindole on Vascular Responsiveness in Diabetes-Induced Aging Rats
Current Aging Science The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress
Current Pharmaceutical Design Axitinib in the Treatment of Head and Neck Malignancies
Current Clinical Pharmacology Subject Index to Volume 1
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Prediction and Targeting of Interaction Interfaces in G-protein Coupled Receptor Oligomers
Current Topics in Medicinal Chemistry The Location of Vascular Flap is Related with Daily Activity Patterns in Non-traumatic Acute Aortic Syndrome in a Chinese Population
Current Signal Transduction Therapy Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design An Overview on Application of Natural Substances Incorporated with Electrospun Nanofibrous Scaffolds to Development of Innovative Wound Dressings
Mini-Reviews in Medicinal Chemistry Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Primary Hyperaldosteronism in the Hypertensive Disease
Current Hypertension Reviews Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research